BRUKINSA is a BTK inhibitor that
was designed to block BTK
BRUKINSA® (zanubrutinib) has been shown to block 100% of BTK in blood cells and 94% to 100% of BTK in lymph nodes when taken at the recommended total daily dose of 320 mg. The signiﬁcance of blocking up to 100% of BTK on treatment responses has not been established.
BRUKINSA is for adults with marginal zone
lymphoma (MZL) when the disease has come back
or did not respond to treatment and who have
received at least one certain type of treatment.
BRUKINSA was approved based on response rate. There is ongoing evaluation to confirm clinical benefit for this use. It is not known if BRUKINSA is safe and effective in children.
Bruton’s tyrosine kinase (BTK) is a protein that has been linked to MZL.